| Target Price | $9.18 |
| Price | $2.48 |
| Potential |
270.16%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Gossamer Bio, Inc. 2026 .
The average Gossamer Bio, Inc. target price is $9.18.
This is
270.16%
register free of charge
$15.75
535.08%
register free of charge
$6.06
144.35%
register free of charge
|
|
| A rating was issued by 15 analysts: 13 Analysts recommend Gossamer Bio, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2026 of
270.16%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 114.70 | 37.92 |
| 66.94% | ||
| EBITDA Margin | -51.52% | -377.71% |
| 633.18% | ||
| Net Margin | -49.29% | -412.67% |
| 737.31% |
10 Analysts have issued a sales forecast Gossamer Bio, Inc. 2025 . The average Gossamer Bio, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2025. The average Gossamer Bio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2025. The average Gossamer Bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.25 | -0.69 |
| 78.81% | 176.00% | |
| P/E | negative | |
| EV/Sales | 14.74 |
10 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Gossamer Bio, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 11 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Sep 10 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 06 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


